1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Retinopathy - Pipeline Review, H2 2020, provides an overview of the Diabetic Retinopathy (Metabolic Disorders) pipeline landscape.
Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings floating in vision (floaters), blurred vision, fluctuating vision, vision loss and difficulty with color perception. The predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Diabetic Retinopathy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Diabetic Retinopathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diabetic Retinopathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 9, 13, 5, 72, 14 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 9 and 2 molecules, respectively.
Diabetic Retinopathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Retinopathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Retinopathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Retinopathy (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Retinopathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionDiabetic Retinopathy - Overview
Diabetic Retinopathy - Therapeutics Development
Diabetic Retinopathy - Therapeutics Assessment
Diabetic Retinopathy - Companies Involved in Therapeutics Development
Diabetic Retinopathy - Drug Profiles
Diabetic Retinopathy - Dormant Projects
Diabetic Retinopathy - Discontinued Products
Diabetic Retinopathy - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Diabetic Retinopathy, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Diabetic Retinopathy - Pipeline by 3SBio Inc, H2 2020
- Diabetic Retinopathy - Pipeline by A6 Pharmaceuticals LLC, H2 2020
- Diabetic Retinopathy - Pipeline by Accuitis Pharmaceuticals Inc, H2 2020
- Diabetic Retinopathy - Pipeline by Adverum Biotechnologies Inc, H2 2020
- Diabetic Retinopathy - Pipeline by Aerie Pharmaceuticals Inc, H2 2020
- Diabetic Retinopathy - Pipeline by Afecta Pharmaceuticals Inc, H2 2020
- Diabetic Retinopathy - Pipeline by Akaal Pharma Pty Ltd, H2 2020
- Diabetic Retinopathy - Pipeline by Antisense Therapeutics Ltd, H2 2020
- Diabetic Retinopathy - Pipeline by Apexian Pharmaceuticals Inc, H2 2020
- Diabetic Retinopathy - Pipeline by Applied Therapeutics Inc, H2 2020
- Diabetic Retinopathy - Pipeline by AptaBio Therapeutics Inc, H2 2020
- Diabetic Retinopathy - Pipeline by Aptamer Sciences Inc, H2 2020
- Diabetic Retinopathy - Pipeline by Araim Pharmaceuticals Inc, H2 2020
- Diabetic Retinopathy - Pipeline by Ascentage Pharma Group International, H2 2020
- Diabetic Retinopathy - Pipeline by BetaStem Therapeutics Inc, H2 2020
- Diabetic Retinopathy - Pipeline by Bio-Thera Solutions Ltd, H2 2020
- Diabetic Retinopathy - Pipeline by Boehringer Ingelheim International GmbH, H2 2020
- Diabetic Retinopathy - Pipeline by Bonac Corp, H2 2020
- Diabetic Retinopathy - Pipeline by CCRP Therapeutics GmbH, H2 2020
- Diabetic Retinopathy - Pipeline by Cell Care Therapeutics Inc, H2 2020
- Diabetic Retinopathy - Pipeline by Charlesson LLC, H2 2020
- Diabetic Retinopathy - Pipeline by Clayton Biotechnologies Inc, H2 2020
- Diabetic Retinopathy - Pipeline by Coherus BioSciences Inc, H2 2020
- Diabetic Retinopathy - Pipeline by Curacle Co Ltd, H2 2020
- Diabetic Retinopathy - Pipeline by Dimerix Ltd, H2 2020
- Diabetic Retinopathy - Pipeline by Elasmogen Ltd, H2 2020
- Diabetic Retinopathy - Pipeline by Emerald Bioscience Inc, H2 2020
- Diabetic Retinopathy - Pipeline by Ennovabio, H2 2020
- Diabetic Retinopathy - Dormant Projects, H2 2020
- Diabetic Retinopathy - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Diabetic Retinopathy, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3SBio Inc
- A6 Pharmaceuticals LLC
- Accuitis Pharmaceuticals Inc
- Adverum Biotechnologies Inc
- Aerie Pharmaceuticals Inc
- Afecta Pharmaceuticals Inc
- Akaal Pharma Pty Ltd
- Antisense Therapeutics Ltd
- Apexian Pharmaceuticals Inc
- Applied Therapeutics Inc
- AptaBio Therapeutics Inc
- Aptamer Sciences Inc
- Araim Pharmaceuticals Inc
- Ascentage Pharma Group International
- BetaStem Therapeutics Inc
- Bio-Thera Solutions Ltd
- Boehringer Ingelheim International GmbH
- Bonac Corp
- CCRP Therapeutics GmbH
- Cell Care Therapeutics Inc
- Charlesson LLC
- Clayton Biotechnologies Inc
- Coherus BioSciences Inc
- Curacle Co Ltd
- Dimerix Ltd
- Elasmogen Ltd
- Emerald Bioscience Inc
- Ennovabio
- Epigen Biosciences Inc
- Everglades Biopharma LLC
- Excitant Therapeutics LLC
- EyeGene Inc
- EyePoint Pharmaceuticals Inc
- F. Hoffmann-La Roche Ltd
- Foresee Pharmaceuticals Co Ltd
- Generium
- Glycadia Inc
- Graybug Vision Inc
- Guangzhou Magpie Pharmaceutical Co Ltd
- HanAll Biopharma Co Ltd
- Hengenix Biotech Inc
- iVeena Delivery Systems Inc
- Kalos Therapeutics Inc
- Kanaph Therapeutics Inc
- Kato Pharmaceuticals Inc
- Kodiak Sciences Inc
- Kowa Co Ltd
- Kubota Vision Inc
- Kuur Therapeutics Ltd
- Lupin Ltd
- Luye Pharma Group Ltd
- Mabion SA
- MingSight Pharmaceuticals Inc
- Mirae Cell Bio Co Ltd
- Mirrx Therapeutics A/S
- Nanoscope Therapeutics Inc
- NeuMedics Inc
- Neurodegeneration Therapeutics Inc
- NGM Biopharmaceuticals Inc
- Novago Therapeutics AG
- Novartis AG
- Novelty Nobility Inc
- Noveome Biotherapeutics Inc
- OccuRx Pty Ltd
- Ocugen Inc
- OcuNexus Therapeutics Inc
- OliPass Corporation
- Opera Therapeutics
- Oxurion NV
- Palatin Technologies Inc
- Panoptes Pharma GesmbH
- Phanes Therapeutics Inc
- PharmAbcine Inc
- Pinotbio Inc
- Profarma
- Protheragen Inc
- PYCTX Ltd
- Regeneron Pharmaceuticals Inc
- RegenxBio Inc
- Retinset SL
- Retrotope Inc
- Reven Pharmaceuticals Inc
- Rezolute Inc
- Ribomic Inc
- Serodus ASA
- Singh Biotechnology LLC
- SiNOPSEE Therapeutics Pte Ltd
- Skyran Biologics Inc
- SmartinBio
- Stealth BioTherapeutics Corp
- SunBio Inc
- Sylentis SAU
- Teraclon IDF SL
- Topadur Pharma AG
- Translatum Medicus Inc
- USA Elixiria Biotech Inc
- Valitor Inc
- VESSL Therapeutics Ltd
- Vitreo Pharma Inc
- Wntgen LLC
- Xbrane Biopharma AB
- YD Life Science Co
- Zih Yuan Tang Biotechnology Co Ltd
